Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 2 peer-reviewed journal articles Updated
Gynecologic Oncology · Fallopian Tube Cancer

Survivorship & Monitoring: Life After Treatment

At a Glance

After fallopian tube cancer treatment, monitoring involves physical exams and CA-125 blood tests every 3 to 6 months. Routine scans are not recommended without symptoms, as treating a recurrence based on symptoms rather than rising blood markers preserves quality of life without impacting survival.

Completing primary treatment for fallopian tube cancer is a major milestone, but it also brings a new phase of care called surveillance [1]. The goal of this phase is to monitor your health closely, manage any long-term side effects, and ensure that any potential recurrence is identified and addressed thoughtfully [2].

The Surveillance Schedule

For the first two years after treatment, you will typically see your Gynecologic Oncologist every 3 to 6 months [1]. After two years, these visits usually occur every 6 to 12 months for up to five years [1]. A standard follow-up visit includes:

  • Physical and Pelvic Exams: These remain the most important tools for monitoring your health [1].
  • CA-125 Blood Tests: This marker can provide early clues about how your body is doing. Note that a small percentage of patients are “non-secretors,” meaning their tumors do not produce elevated CA-125 levels. If this applies to you, your team will track your health through symptoms and other means [1].

Why “More Scans” Isn’t Always Better

It is natural to feel that frequent CT or PET scans would provide “peace of mind,” but international guidelines generally discourage routine imaging for patients who have no symptoms and stable CA-125 levels [1].

A major clinical trial showed that waiting for symptoms to appear before restarting treatment preserves your quality of life without negatively impacting your overall survival outcomes [1]. Starting chemotherapy earlier based solely on a rising CA-125 score just adds months of side effects without a survival benefit [1]. By limiting scans to times when they are medically necessary, your team avoids unnecessary radiation exposure and reduces the psychological stress known as scanxiety [1].

Managing Long-Term Side Effects

The goal of survivorship is not just “living,” but living well. Several common side effects may persist after treatment:

  • Peripheral Neuropathy: This is a tingling, numbness, or pain in the hands and feet caused by chemotherapy (specifically paclitaxel) [2]. While there are no proven ways to prevent this, the medication duloxetine is supported by evidence to help manage established nerve pain [2].
  • Surgical Menopause: Because treatment often involves the removal of the ovaries, many survivors experience sudden menopause. This can lead to hot flashes, vaginal dryness, and bone density loss [2]. Management may include non-hormonal options or, in some specific cases, hormone replacement therapy (HRT) after a detailed discussion of risks and benefits with your oncologist.
  • Fatigue and Brain Fog: “Chemo brain” and persistent tiredness are very common [2]. Evidence suggests that gentle, consistent physical activity and prioritizing sleep can help the body recover its energy levels over time [2].

Your survivorship journey is unique. Using a survivorship care plan—a document that summarizes your treatment and outlines your future monitoring—can help you and your primary care doctor stay coordinated in the years ahead.

Common questions in this guide

How often will I need follow-up appointments after completing treatment?
For the first two years, you will typically see your gynecologic oncologist every 3 to 6 months. After two years, these follow-up visits usually occur every 6 to 12 months for up to five years.
Why doesn't my doctor recommend frequent imaging scans to monitor for recurrence?
International guidelines discourage routine CT or PET scans for patients who have no symptoms and stable CA-125 levels. Limiting scans avoids unnecessary radiation exposure and reduces anxiety, without negatively impacting your long-term outcomes.
What happens if my CA-125 levels rise but I don't have any symptoms?
Studies show that waiting for symptoms to appear before restarting treatment preserves your quality of life without lowering overall survival rates. Starting chemotherapy earlier based solely on a blood test adds months of side effects without a survival benefit.
What can be done for my persistent neuropathy after chemotherapy?
Nerve pain, numbness, or tingling in your hands and feet is often caused by chemotherapy drugs like paclitaxel. While it cannot always be prevented, the medication duloxetine has been shown to effectively manage established nerve pain.
How can we safely manage the symptoms of surgical menopause?
Since treatment often involves removing the ovaries, you may experience sudden menopause symptoms like hot flashes or vaginal dryness. Management may include non-hormonal therapies or hormone replacement therapy, which you should discuss thoroughly with your oncologist.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific follow-up schedule for physical exams and CA-125 tests for the next two years?
  2. 2.If my CA-125 level rises but I have no symptoms, what is our plan for next steps?
  3. 3.Are there specific 'red flag' symptoms I should report immediately between scheduled visits?
  4. 4.What can be done for my persistent neuropathy, and am I a candidate for duloxetine or other therapies?
  5. 5.How can we safely manage the symptoms of surgical menopause, given my specific tumor type?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (2)
  1. 1

    Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

    Rustin GJ, van der Burg ME, Griffin CL, et al.

    Lancet (London, England) 2010; (376(9747)):1155-63 doi:10.1016/S0140-6736(10)61268-8.

    PMID: 20888993
  2. 2

    Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update.

    Loprinzi CL, Lacchetti C, Bleeker J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(28)):3325-3348 doi:10.1200/JCO.20.01399.

    PMID: 32663120

This page provides educational information on survivorship and monitoring for fallopian tube cancer. Always consult your gynecologic oncologist to establish a personalized follow-up care plan.

Get notified when new evidence is published on Malignant tumor of fallopian tubes.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.